Licensed rabies virus vaccines based on whole inactivated virus are effective in humans.
However, there is a lack of detailed investigations of the elicited immune response, and
whether responses can be improved using novel vaccine platforms. Here we show that two
doses of a lipid nanoparticle-formulated unmodified mRNA vaccine encoding the rabies
virus glycoprotein (RABV-G) induces higher levels of RABV-G specific plasmablasts and T
cells in blood, and plasma cells in the bone marrow compared to two doses of Rabipur in …